港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

巨子生物

63.700

+2.8004.60%

成交量：263.82萬

成交額：1.67億

市值：659.93億

市盈率：28.67

高：65.000

開：62.750

低：61.650

收：60.900

資料載入中...

總覽公司新聞公告

國金證券：維持鉅子生物(02367)“買入”評級骨修復材料獲批三類械

鉅子生物(02367)出現大手成交10.5萬股，成交價$51.5，涉資540.75萬

阿斯达克财经

鉅子生物(2367.HK)：首個III類醫療器械註冊證獲批前景可期

鉅子生物12月13日獲南向資金加倉95.54萬股

醫美賽道迎來一波新玩家！

【券商聚焦】廣發證券維持鉅子生物(02367)“買入”評級指醫美矩陣豐富

港股概念追蹤|2024年美妝消費恢復正常購買週期美妝個護新國貨崛起（附概念股）

異動解讀 | 鉅子生物(02367)獲廣發買入評級並有醫美新藥獲批,盤中股價大漲6.26%

廣發證券：維持鉅子生物(02367)“買入”評級合理價值55.72港元

鉅子生物盤中異動下午盤急速拉昇5.07%

鉅子生物(02367)上漲5.07%，報52.85元/股

南向資金12月11日淨賣出鉅子生物3.86萬股連續3日減持

鉅子生物12月11日主力資金流出125萬元連續3日減倉

鉅子生物盤中異動快速拉昇5.08%報53.750港元

醫藥股再獲資金關注鉅子生物大漲超8%

異動解讀 | 鉅子生物股價盤中大漲6.86% 主力產品獲優先審批增強長期發展信心

【港股通】鉅子生物(02367)升逾7% “注射用重組膠原蛋白填充劑”獲優先審批

港股異動 | 鉅子生物(02367)漲超8% 旗下“注射用重組膠原蛋白填充劑”獲優先審批

鉅子生物(02367)上漲7.5%，報50.9元/股

鉅子生物盤中異動股價大漲6.65%報50.500港元

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/02367/news?page=8"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02367","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02367\",,,,,undefined,":{"symbol":"02367","market":"HK","secType":"STK","nameCN":"巨子生物","latestPrice":63.7,"timestamp":1744078823660,"preClose":60.9,"halted":0,"volume":2638218,"delay":0,"floatShares":1036000000,"shares":1036000000,"eps":2.2215534268873607,"marketStatus":"交易中","change":2.8,"latestTime":"04-08 10:20:23","open":62.75,"high":65,"low":61.65,"amount":166858501,"amplitude":0.055008,"askPrice":63.7,"askSize":6200,"bidPrice":63.65,"bidSize":4800,"shortable":3,"etf":0,"ttmEps":2.1788749573687687,"tradingStatus":2,"nextMarketStatus":{"tag":"午間休市","tradingStatus":4,"beginTime":1744084800000},"marketStatusCode":2,"adr":0,"listingDate":1667491200000,"exchange":"SEHK","adjPreClose":60.9,"dividendRate":0.015228,"openAndCloseTimeList":[[1744075800000,1744084800000],[1744088400000,1744099200000]],"volumeRatio":3.215281,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02367\",,,,,undefined,":{"symbol":"02367","floatShares":1036000000,"roa":"21.88%","roe":"35.88%","lyrEps":2.221553,"volumeRatio":3.215281,"shares":1036000000,"dividePrice":0.97,"high":65,"amplitude":0.055008,"preClose":60.9,"low":61.65,"week52Low":35,"pbRate":"8.78","psRate":"11.26","week52High":75.2,"institutionHeld":0,"latestPrice":63.7,"committee":-0.127273,"eps":2.2215534268873607,"divideRate":0.015228,"volume":2638218,"delay":0,"ttmEps":2.1788749573687687,"open":62.75,"prevYearClose":49.9,"prevWeekClose":71.4,"prevMonthClose":70.45,"prevQuarterClose":70.45,"fiveDayClose":70.45,"twentyDayClose":68.85,"sixtyDayClose":46.25},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02367\",pageSize:20,pageCount:8,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2492773789","title":"國金證券：維持鉅子生物(02367)“買入”評級 骨修復材料獲批三類械","url":"https://stock-news.laohu8.com/highlight/detail?id=2492773789","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492773789?lang=zh_tw&edition=fundamental","pubTime":"2024-12-18 17:14","pubTimestamp":1734513264,"startTime":"0","endTime":"0","summary":"事件：国家药监局12月17日官网公示，巨子生物骨修复材料获批三类医疗器械，符合此前招股书24Q4拿证预期。供给端看，据药监局，除巨子生物外，奥精医疗科技、天津市赛宁生物等旗下的胶原蛋白+羟基磷灰石复合的骨修复材料已获批三类械。2)国内获批进展：目前羟基磷灰石材料在国内医美领域尚无合规三类证。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1226535.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02367"],"gpt_icon":0},{"id":"2492978136","title":"鉅子生物(02367)出現大手成交10.5萬股，成交價$51.5，涉資540.75萬","url":"https://stock-news.laohu8.com/highlight/detail?id=2492978136","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492978136?lang=zh_tw&edition=fundamental","pubTime":"2024-12-18 14:48","pubTimestamp":1734504480,"startTime":"0","endTime":"0","summary":"[大手成交]巨子生物(02367)在下午02:48出现大手成交，成交量为10.5万，成交价为港币$51.5，涉资540.75万。至目前为止，股价跌0.865%，今日最高价为$52.9，而最低价为$50.8，总成交量为360.25万股，总成交金额港币$1.858亿。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180815142908460_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180815142908460_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2412183822/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1207","LU2488822045.USD","02367"],"gpt_icon":0},{"id":"2492204976","title":"鉅子生物(2367.HK)：首個III類醫療器械註冊證獲批 前景可期","url":"https://stock-news.laohu8.com/highlight/detail?id=2492204976","media":"华泰证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492204976?lang=zh_tw&edition=fundamental","pubTime":"2024-12-18 00:00","pubTimestamp":1734451200,"startTime":"0","endTime":"0","summary":"17 日公司公众号披露获得首个III 类医疗器械注册证，为骨修复材料。另一款颈纹产品近期已进入优先审批绿色通道另据药监局，巨子生物的另外一款医疗器械产品“注射用重组胶原蛋白填充剂”属于“列入国家重点研发计划的医疗器械”，符合优先审批条件。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241218155648ab813a93&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241218155648ab813a93&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09996","BK1583","BK1100","09997","BK1222","02367","BK1207","BK1574","LU2488822045.USD"],"gpt_icon":0},{"id":"2491147686","title":"鉅子生物12月13日獲南向資金加倉95.54萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2491147686","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491147686?lang=zh_tw&edition=fundamental","pubTime":"2024-12-16 09:30","pubTimestamp":1734312619,"startTime":"0","endTime":"0","summary":"12月13日, 南向资金增持巨子生物95.54万股。截止当日收盘，港股通共持有巨子生物17156.38万股，占流通股16.68%。巨子生物近5个交易日上涨0.68%，港股通累计减持107.22万股；近20个交易日上涨4.34%，港股通累计减持116.41万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216093245a1f1a80c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216093245a1f1a80c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02367","LU2488822045.USD","BK1207"],"gpt_icon":0},{"id":"2491578568","title":"醫美賽道迎來一波新玩家！","url":"https://stock-news.laohu8.com/highlight/detail?id=2491578568","media":"青眼","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491578568?lang=zh_tw&edition=fundamental","pubTime":"2024-12-15 20:58","pubTimestamp":1734267480,"startTime":"0","endTime":"0","summary":"欧莱雅集团此举也被视作入局医美赛道的信号，引发行业广泛关注。代表性事件则是欧莱雅集团与颜术医美达成深度合作，进一步为欧莱雅集团旗下修丽可品牌提供研发尖端科技创新。实际上，欧莱雅集团加码医美赛道并非行业首例。而近期刚更名的“丸美生物”，同样在重组胶原赛道进行了一系列布局。医研共创是必经之路美妆企业/品牌会扎堆入局医美赛道并非一蹴而就，这一普遍现象背后实则早已有迹可循。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-12-15/doc-inczqazp3427773.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1207","09996","09997","LU2488822045.USD","BK1574","BK1222","BK1100","BK1583","02367"],"gpt_icon":0},{"id":"2491190983","title":"【券商聚焦】廣發證券維持鉅子生物(02367)“買入”評級 指醫美矩陣豐富","url":"https://stock-news.laohu8.com/highlight/detail?id=2491190983","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491190983?lang=zh_tw&edition=fundamental","pubTime":"2024-12-13 13:54","pubTimestamp":1734069264,"startTime":"0","endTime":"0","summary":"该行续指，公司当前市值对应24/25年PE23/18倍，化妆品业务稳健，支撑当前市值，医美预期始终是额外期权。预计公司24-26年归母净利润21.20、26.58、31.74亿元，考虑重组胶原蛋白市场的强增势，给予公司24年25倍PE估值，对应合理价值55.72港元/股，维持“买入”评级。","market":"sh","thumbnail":"https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1949614","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02367","01776"],"gpt_icon":0},{"id":"2491839659","title":"港股概念追蹤|2024年美妝消費恢復正常購買週期  美妝個護新國貨崛起（附概念股）","url":"https://stock-news.laohu8.com/highlight/detail?id=2491839659","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491839659?lang=zh_tw&edition=fundamental","pubTime":"2024-12-13 10:09","pubTimestamp":1734055748,"startTime":"0","endTime":"0","summary":"今年“双11”活动期间，珀莱雅旗下各品牌销售情况保持良好态势。丸美天猫旗舰店销售额同比增长34%，稳居天猫国货眼霜第一。国泰君安表示，经历2022年消费承压、2023年消费者端去库存后，2024年美妆消费恢复正常购买周期，行业景气度环比改善，双十一线上美妆实现双位数增长。国泰君安展望2025年市场风险偏好显著修复，美护板块因其变化较多、且国货整体呈崛起趋势，成长属性明显，风格上显著受益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1224375.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HSCEI","02145","LU2488822045.USD","02367","BK1207","HSTECH","YANG","01318"],"gpt_icon":1},{"id":"1102915591","title":"異動解讀 | 鉅子生物(02367)獲廣發買入評級並有醫美新藥獲批,盤中股價大漲6.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=1102915591","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102915591?lang=zh_tw&edition=fundamental","pubTime":"2024-12-12 16:30","pubTimestamp":1733992237,"startTime":"0","endTime":"0","summary":"巨子生物(02367)股价今日盘中出现大涨行情,大涨6.26%,引发市场关注。分析显示,这主要与两个利好消息有关:\n\n首先,券商广发证券发布研究报告,维持巨子生物\"买入\"评级,预计公司未来3年归母净利润将持续增长,并给予公司合理价值55.72港元的目标价,对公司前景予以看好。\n\n其次,巨子生物旗下针对颈纹的\"注射用重组胶原蛋白填充剂\"获得优先审批。这表明公司在医美领域的创新研发取得进展,为进一步开拓医美市场奠定了基础。据了解,巨子生物目前在医美领域的在研产品共有4款,产品矩阵丰富。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 巨子生物(02367)获广发买入评级并有医美新药获批,盘中股价大涨6.26%","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02367"],"gpt_icon":0},{"id":"2490434879","title":"廣發證券：維持鉅子生物(02367)“買入”評級 合理價值55.72港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2490434879","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490434879?lang=zh_tw&edition=fundamental","pubTime":"2024-12-12 16:25","pubTimestamp":1733991910,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，广发证券发布研究报告称，维持巨子生物“买入”评级，预计2024-26年归母净利润21.20、26.58、31.74亿元，考虑重组胶原蛋白市场的强增势，予24年25倍PE估值，合理价值55.72港元。公司化妆品业务稳健，支撑当前市值，医美预期始终是额外期权。12月5日，巨子生物旗下的“注射用重组胶原蛋白填充剂”获得优先审批，“该产品属于列入国家重点研发计划的医疗器械”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1223974.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02367","01776"],"gpt_icon":0},{"id":"2490820737","title":"鉅子生物盤中異動 下午盤急速拉昇5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2490820737","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490820737?lang=zh_tw&edition=fundamental","pubTime":"2024-12-12 15:02","pubTimestamp":1733986957,"startTime":"0","endTime":"0","summary":"2024年12月12日下午盘15时02分，巨子生物股票出现异动，股价快速拉升5.07%。截至发稿，该股报52.850港元/股，成交量308.342万股，换手率0.30%，振幅6.36%。巨子生物股票所在的生物技术行业中，整体涨幅为0.08%。其相关个股中，思路迪医药股份、晶泰控股-P、帝王国际投资涨幅较大，振幅较大的相关个股有思路迪医药股份、晶泰控股-P、帝王国际投资，振幅分别为38.70%、19.44%、18.75%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121215023795e923d3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121215023795e923d3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2488822045.USD","02367","BK1207"],"gpt_icon":0},{"id":"2490787428","title":"鉅子生物(02367)上漲5.07%，報52.85元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2490787428","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490787428?lang=zh_tw&edition=fundamental","pubTime":"2024-12-12 15:02","pubTimestamp":1733986944,"startTime":"0","endTime":"0","summary":"12月12日，巨子生物(02367)盘中上涨5.07%，截至15:02，报52.85元/股，成交1.59亿元。巨子生物主营业务为研发和生产功效性护肤品、医疗器械和功能性食品，核心技术是采用自有的合成生物学技术开发重组胶原蛋白和稀有人参皂苷等生物活性成分。公司拥有93项专利和专利申请，其重组胶原蛋白技术在中国是首个获得专利的，并曾两次获得重要的技术奖励。截至2024年中报，巨子生物营业总收入25.4亿元、净利润9.83亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/12/12150246307014.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU2488822045.USD","BK1207","02367"],"gpt_icon":0},{"id":"2490846783","title":"南向資金12月11日淨賣出鉅子生物3.86萬股 連續3日減持","url":"https://stock-news.laohu8.com/highlight/detail?id=2490846783","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490846783?lang=zh_tw&edition=fundamental","pubTime":"2024-12-12 09:30","pubTimestamp":1733967023,"startTime":"0","endTime":"0","summary":"12月11日，南向资金减持巨子生物3.86万股连续3日减持。截止当日收盘，港股通共持有巨子生物17065.54万股，占流通股16.58%。巨子生物近5个交易日上涨2.86%，港股通累计减持206.58万股；近20个交易日下跌1.76%，港股通累计减持331.08万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241212093230ab710123&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241212093230ab710123&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02367","BK1207","LU2488822045.USD"],"gpt_icon":0},{"id":"2490688061","title":"鉅子生物12月11日主力資金流出125萬元 連續3日減倉","url":"https://stock-news.laohu8.com/highlight/detail?id=2490688061","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490688061?lang=zh_tw&edition=fundamental","pubTime":"2024-12-11 16:16","pubTimestamp":1733904995,"startTime":"0","endTime":"0","summary":"12月11日, 巨子生物股价跌1.08%，报收50.30元，成交金额1.19亿元，换手率0.23%，振幅3.15%，量比0.53。巨子生物今日主力资金净流出125万元，连续3日净流出，上一交易日主力净流出147万元，今日环比减少14.97%。近一年数据显示，该股主力连续3日净流出后，次日下跌概率为37.50%，平均跌幅为2.41%。该股近5个交易日上涨2.56%，主力资金累计净流入2874万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入1.06亿元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241211161703ab6efad5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241211161703ab6efad5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2488822045.USD","02367","BK1207"],"gpt_icon":0},{"id":"2490039017","title":"鉅子生物盤中異動 快速拉昇5.08%報53.750港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2490039017","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490039017?lang=zh_tw&edition=fundamental","pubTime":"2024-12-10 09:38","pubTimestamp":1733794713,"startTime":"0","endTime":"0","summary":"2024年12月10日早盘09时38分，巨子生物股票出现异动，股价急速拉升5.08%。截至发稿，该股报53.750港元/股，成交量65.98万股，换手率0.06%，振幅3.91%。资金方面，该股资金流入1680.09万港元，流出902.651万港元。巨子生物股票所在的生物技术行业中，整体涨幅为0.99%。其相关个股中，思路迪医药股份、百奥赛图-B、贝康医疗-B涨幅较大，振幅较大的相关个股有晶泰控股-P、来凯医药-B、药明巨诺-B，振幅分别为11.30%、8.29%、7.91%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241210093833a1e1f318&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241210093833a1e1f318&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02367","BK1207","LU2488822045.USD"],"gpt_icon":0},{"id":"2489074423","title":"醫藥股再獲資金關注 鉅子生物大漲超8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2489074423","media":"市场资讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489074423?lang=zh_tw&edition=fundamental","pubTime":"2024-12-06 10:24","pubTimestamp":1733451840,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！　　财联社12月6日讯 今日港股医药股多数上涨。截至发稿，云康集团、永泰生物-B、巨子生物、宜明昂科-B（）分别上涨16.67%、11.54%、8.13%、6.27%。　　从上图来看，巨子生物表现居前，该公司一度涨近9%。　　宜明昂科近日发布公告，宣布公司已获中国国家药监局批准进行IMM0306用于治疗狼疮性肾炎的II期临床试验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/2024-12-06/doc-incynvuq5706618.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02367","09939","159938","BK1207","BK1515","BK1574","LU2488822045.USD","BK1161"],"gpt_icon":0},{"id":"1167613969","title":"異動解讀 | 鉅子生物股價盤中大漲6.86% 主力產品獲優先審批 增強長期發展信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1167613969","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167613969?lang=zh_tw&edition=fundamental","pubTime":"2024-12-06 10:21","pubTimestamp":1733451690,"startTime":"0","endTime":"0","summary":"生物科技公司巨子生物(02367)今日盘中大涨6.86%,引起市场广泛关注。\n\n利好消息是,巨子生物旗下主力产品\"注射用重组胶原蛋白填充剂\"获得国家药监局批准优先审评。该产品属于国家重点研发计划范畴,有望加快上市进程。\n\n作为巨子生物重要收入来源,这款产品的利好消息无疑增强了市场对公司长期发展前景的信心。投资者预期公司未来将从产品上市销售中获益,推升股价大涨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02367"],"gpt_icon":0},{"id":"2489142531","title":"【港股通】鉅子生物(02367)升逾7% “注射用重組膠原蛋白填充劑”獲優先審批","url":"https://stock-news.laohu8.com/highlight/detail?id=2489142531","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489142531?lang=zh_tw&edition=fundamental","pubTime":"2024-12-06 09:54","pubTimestamp":1733450067,"startTime":"0","endTime":"0","summary":"金吾财讯 | 巨子生物 早盘股价震荡扬升，截至发稿，涨7.07%，报50.7港元，成交额7460.71万港元。据《结果公示》，巨子生物的“注射用重组胶原蛋白填充剂”属于“列入国家重点研发计划的医疗器械”，符合优先审批情形的项目，拟定予以优先审批。该行表示，公司作为重组胶原蛋白龙头，凭借多元化产品矩阵和渠道优势，业绩有望持续高增。维持“买入”评级。","market":"other","thumbnail":"https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1949110","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["YANG","BK1207","HSCEI","02367","HSTECH","LU2488822045.USD","07226"],"gpt_icon":0},{"id":"2489447224","title":"港股異動 | 鉅子生物(02367)漲超8% 旗下“注射用重組膠原蛋白填充劑”獲優先審批","url":"https://stock-news.laohu8.com/highlight/detail?id=2489447224","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489447224?lang=zh_tw&edition=fundamental","pubTime":"2024-12-06 09:37","pubTimestamp":1733449037,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，巨子生物(02367)涨超8%，截至发稿，涨8.87%，报51.55港元，成交额4957.53万港元。消息面上，12月5日，国家药品监督管理局医疗器械技术审评中心（CMDE）发布《医疗器械优先审批申请审核结果公示（2024年第17号）》（简称“《结果公示》”）。据《结果公示》，巨子生物的“注射用重组胶原蛋白填充剂（受理号：CQZ2402149）”属于“列入国家重点研发计划的医疗器械”，符合优先审批情形的项目，拟定予以优先审批。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1221201.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02367","BK1207","LU2488822045.USD"],"gpt_icon":0},{"id":"2489447930","title":"鉅子生物(02367)上漲7.5%，報50.9元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2489447930","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489447930?lang=zh_tw&edition=fundamental","pubTime":"2024-12-06 09:30","pubTimestamp":1733448610,"startTime":"0","endTime":"0","summary":"12月6日，巨子生物(02367)盘中上涨7.5%，截至09:30，报50.9元/股，成交335.37万元。巨子生物主营业务为研发和生产功效性护肤品、医疗器械和功能性食品，核心技术是采用自有的合成生物学技术开发重组胶原蛋白和稀有人参皂苷等生物活性成分。公司拥有93项专利和专利申请，其重组胶原蛋白技术在中国是首个获得专利的，并曾两次获得重要的技术奖励。截至2024年中报，巨子生物营业总收入25.4亿元、净利润9.83亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/12/06093046085870.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU2488822045.USD","02367","BK1207"],"gpt_icon":0},{"id":"2489644016","title":"鉅子生物盤中異動 股價大漲6.65%報50.500港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2489644016","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489644016?lang=zh_tw&edition=fundamental","pubTime":"2024-12-06 09:30","pubTimestamp":1733448606,"startTime":"0","endTime":"0","summary":"2024年12月06日早盘09时30分，巨子生物股票出现异动，股价急速上涨6.65%。截至发稿，该股报50.500港元/股，成交量4.92万股，换手率0.00%，振幅1.37%。资金方面，该股资金流入27.385万港元，流出37.104万港元。巨子生物股票所在的生物技术行业中，整体涨幅为0.37%。其相关个股中，巨子生物、歌礼制药-B、乐普生物-B涨幅较大，振幅较大的相关个股有再鼎医药、乐普生物-B、巨子生物，振幅分别为2.05%、1.50%、1.06%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241206093006a1d7ce9c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241206093006a1d7ce9c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2488822045.USD","BK1207","02367"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":8,"totalSize":200}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02367\",params:#limit:5,,,undefined,":[{"date":"2025-06-17","symbol":"02367","amount":0.5921,"announcedDate":"2025-03-26","type":"dividend","lastAmount":null,"market":"HK","newRecordDate":"2025-06-18","defaultRemindTime":1750123800000,"name":"巨子生物","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-08-29","payableDate":"2025-06-18","currency":"CNY","dateTimestamp":1750089600000,"payDate":"2025-08-29"},{"date":"2025-03-26","symbol":"02367","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1742952600000,"name":null,"time":"盤後","dateTimestamp":1742918400000,"actualEps":null},{"date":"2024-08-19","symbol":"02367","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724031000000,"name":null,"time":"盤後","dateTimestamp":1723996800000,"actualEps":null},{"date":"2024-06-17","symbol":"02367","amount":0.97,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"HK","newRecordDate":"2024-06-18","defaultRemindTime":1718587800000,"name":"巨子生物","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-07-05","payableDate":"2024-06-18","currency":"HKD","dateTimestamp":1718553600000,"payDate":"2024-07-05"},{"date":"2024-03-25","symbol":"02367","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1711330200000,"name":null,"time":"","dateTimestamp":1711296000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02367\",market:\"HK\",,,undefined,":[{"executeDate":"2024-06-17","recordDate":"2024-06-18","paymentDate":"2024-07-05","value":0.97,"currency":"HKD"},{"executeDate":"2025-06-17","recordDate":"2025-06-18","paymentDate":"2025-08-29","value":0.5921,"currency":"CNY"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02367\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.3529,"buy":0.6471,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6471,"analysts":17,"updateTime":1743350400000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02367\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02367","date":"2025-04-03","current":32.960917,"percent":0.76819,"low":18.546195,"twenty":25.84406,"median":29.176551,"eighty":33.68679,"high":60.214956,"avg":30.40921,"sd":6.612573,"marketCap":72606945600},"quantilePoints":[{"date":"2022-11-04","current":28.694216,"twenty":26.512834,"median":26.542085,"eighty":27.833364,"marketCap":25968654960},{"date":"2022-11-11","current":35.577583,"twenty":27.402937,"median":34.819032,"eighty":37.211633,"marketCap":32485133920},{"date":"2022-11-18","current":30.409033,"twenty":29.071802,"median":32.325114,"eighty":36.373143,"marketCap":27670720360},{"date":"2022-11-25","current":29.089974,"twenty":29.309257,"median":30.328688,"eighty":34.970742,"marketCap":26260437600},{"date":"2022-12-02","current":29.440115,"twenty":28.58665,"median":29.786096,"eighty":33.378719,"marketCap":27035200000},{"date":"2022-12-09","current":33.170723,"twenty":28.69893,"median":30.328688,"eighty":33.541593,"marketCap":30744000000},{"date":"2022-12-16","current":33.617702,"twenty":28.859591,"median":31.890871,"eighty":33.525219,"marketCap":31085600000},{"date":"2022-12-23","current":32.235512,"twenty":29.23003,"median":32.061881,"eighty":33.375102,"marketCap":29816800000},{"date":"2022-12-30","current":35.028223,"twenty":29.440115,"median":32.235512,"eighty":33.644993,"marketCap":32793600000},{"date":"2023-01-06","current":34.259259,"twenty":29.598569,"median":32.356077,"eighty":33.906187,"marketCap":32403200000},{"date":"2023-01-13","current":37.514633,"twenty":29.683286,"median":32.593587,"eighty":35.138095,"marketCap":36160800000},{"date":"2023-01-20","current":39.320225,"twenty":29.767789,"median":33.170723,"eighty":36.075015,"marketCap":37576000000},{"date":"2023-01-27","current":41.405428,"twenty":29.847916,"median":33.242723,"eighty":36.22764,"marketCap":39576800000},{"date":"2023-02-03","current":46.017337,"twenty":30.125824,"median":33.502098,"eighty":37.981351,"marketCap":44212800000},{"date":"2023-02-10","current":48.646066,"twenty":30.280481,"median":33.687805,"eighty":39.317619,"marketCap":46457600000},{"date":"2023-02-17","current":47.305048,"twenty":30.475064,"median":33.964048,"eighty":41.148897,"marketCap":44749600000},{"date":"2023-02-24","current":46.898265,"twenty":30.969524,"median":34.88282,"eighty":44.591745,"marketCap":43822400000},{"date":"2023-03-03","current":48.206405,"twenty":31.89643,"median":35.69024,"eighty":46.759698,"marketCap":45335200000},{"date":"2023-03-17","current":60.214956,"twenty":31.932315,"median":36.041848,"eighty":47.552658,"marketCap":56754400000},{"date":"2023-03-24","current":51.699724,"twenty":32.016899,"median":36.568073,"eighty":48.347792,"marketCap":49288000000},{"date":"2023-03-31","current":40.925047,"twenty":32.156582,"median":37.514633,"eighty":48.347792,"marketCap":46848000000},{"date":"2023-04-06","current":40.652856,"twenty":32.21578,"median":38.432644,"eighty":48.279626,"marketCap":46506400000},{"date":"2023-04-14","current":37.246115,"twenty":32.289273,"median":38.307612,"eighty":48.226605,"marketCap":42651200000},{"date":"2023-04-21","current":33.385259,"twenty":32.343692,"median":38.098031,"eighty":47.893759,"marketCap":38210400000},{"date":"2023-04-28","current":30.285025,"twenty":32.289273,"median":37.591448,"eighty":47.642868,"marketCap":34404000000},{"date":"2023-05-05","current":26.161165,"twenty":31.945964,"median":37.33158,"eighty":47.490756,"marketCap":29768000000},{"date":"2023-05-12","current":30.574645,"twenty":30.692284,"median":36.23263,"eighty":47.274687,"marketCap":34550400000},{"date":"2023-05-19","current":31.711515,"twenty":30.746535,"median":35.923479,"eighty":47.115193,"marketCap":35331200000},{"date":"2023-05-25","current":31.182824,"twenty":30.822604,"median":35.69024,"eighty":46.935066,"marketCap":34599200000},{"date":"2023-06-02","current":32.039153,"twenty":30.742861,"median":35.028223,"eighty":46.759698,"marketCap":35428800000},{"date":"2023-06-09","current":32.262222,"twenty":30.684805,"median":34.15987,"eighty":46.167812,"marketCap":35624000000},{"date":"2023-06-16","current":32.772734,"twenty":30.742861,"median":33.693297,"eighty":45.892894,"marketCap":36014400000},{"date":"2023-06-23","current":31.032471,"twenty":30.757557,"median":33.682729,"eighty":45.395124,"marketCap":33916000000},{"date":"2023-06-30","current":31.360803,"twenty":30.757557,"median":33.502098,"eighty":44.617559,"marketCap":33964800000},{"date":"2023-07-07","current":31.376956,"twenty":30.759705,"median":33.358016,"eighty":44.488487,"marketCap":33916000000},{"date":"2023-07-14","current":31.254408,"twenty":30.81937,"median":33.206723,"eighty":42.385946,"marketCap":34257600000},{"date":"2023-07-21","current":29.61115,"twenty":30.759705,"median":32.931722,"eighty":41.535665,"marketCap":32305600000},{"date":"2023-07-28","current":31.165322,"twenty":30.717545,"median":32.723027,"eighty":41.405428,"marketCap":33964800000},{"date":"2023-08-04","current":32.76763,"twenty":30.739187,"median":32.639512,"eighty":41.393979,"marketCap":35770400000},{"date":"2023-08-11","current":32.773868,"twenty":30.757557,"median":32.603384,"eighty":41.176747,"marketCap":35575200000},{"date":"2023-08-18","current":30.610294,"twenty":30.757557,"median":32.513854,"eighty":41.037499,"marketCap":32988800000},{"date":"2023-08-25","current":31.726668,"twenty":30.759705,"median":32.346784,"eighty":40.925047,"marketCap":34208800000},{"date":"2023-09-01","current":27.573424,"twenty":30.671209,"median":32.32831,"eighty":40.652856,"marketCap":36697600000},{"date":"2023-09-08","current":26.75169,"twenty":30.572064,"median":32.277824,"eighty":40.648282,"marketCap":35184800000},{"date":"2023-09-15","current":25.993592,"twenty":30.285025,"median":32.235512,"eighty":40.62978,"marketCap":34452800000},{"date":"2023-09-22","current":25.737943,"twenty":29.809068,"median":32.045764,"eighty":40.128892,"marketCap":33964800000},{"date":"2023-09-29","current":25.066298,"twenty":29.656075,"median":31.997803,"eighty":39.81665,"marketCap":33135200000},{"date":"2023-10-06","current":25.484582,"twenty":29.406098,"median":31.918666,"eighty":39.533705,"marketCap":33672000000},{"date":"2023-10-13","current":24.08012,"twenty":28.952772,"median":31.841433,"eighty":39.348774,"marketCap":31768800000},{"date":"2023-10-20","current":22.598372,"twenty":28.090884,"median":31.767659,"eighty":39.309801,"marketCap":29768000000},{"date":"2023-10-27","current":22.348635,"twenty":27.619397,"median":31.711663,"eighty":39.282609,"marketCap":29426400000},{"date":"2023-11-03","current":25.394448,"twenty":27.541831,"median":31.642548,"eighty":39.168886,"marketCap":33525600000},{"date":"2023-11-10","current":25.843419,"twenty":27.016595,"median":31.492944,"eighty":38.901953,"marketCap":34111200000},{"date":"2023-11-17","current":25.355932,"twenty":26.744612,"median":31.467436,"eighty":38.544946,"marketCap":33769600000},{"date":"2023-11-24","current":25.803053,"twenty":26.578324,"median":31.402883,"eighty":38.289787,"marketCap":34648000000},{"date":"2023-12-01","current":25.805078,"twenty":26.361375,"median":31.373452,"eighty":38.186355,"marketCap":34794400000},{"date":"2023-12-08","current":23.911147,"twenty":26.187226,"median":31.314709,"eighty":38.124793,"marketCap":32110400000},{"date":"2023-12-15","current":23.015122,"twenty":25.978956,"median":31.279712,"eighty":37.928033,"marketCap":31085600000},{"date":"2023-12-22","current":23.970526,"twenty":25.934891,"median":31.256547,"eighty":37.726838,"marketCap":32354400000},{"date":"2023-12-29","current":25.605578,"twenty":25.922833,"median":31.253927,"eighty":37.637537,"marketCap":34745600000},{"date":"2024-01-05","current":24.881987,"twenty":25.805078,"median":31.237017,"eighty":37.514633,"marketCap":33525600000},{"date":"2024-01-12","current":25.701327,"twenty":25.757517,"median":31.165322,"eighty":37.417045,"marketCap":34648000000},{"date":"2024-01-19","current":24.032983,"twenty":25.700075,"median":31.138965,"eighty":37.246115,"marketCap":32354400000},{"date":"2024-01-26","current":24.563567,"twenty":25.531167,"median":31.049171,"eighty":36.903516,"marketCap":32940000000},{"date":"2024-02-02","current":22.773078,"twenty":25.419215,"median":30.993085,"eighty":36.23263,"marketCap":30500000000},{"date":"2024-02-09","current":24.329361,"twenty":25.355932,"median":30.81937,"eighty":36.207681,"marketCap":32744800000},{"date":"2024-02-16","current":25.846624,"twenty":25.369207,"median":30.758631,"eighty":36.108181,"marketCap":34794400000},{"date":"2024-02-23","current":26.457355,"twenty":25.369207,"median":30.717545,"eighty":35.899805,"marketCap":35428800000},{"date":"2024-03-01","current":26.003824,"twenty":25.387892,"median":30.635655,"eighty":35.803782,"marketCap":34843200000},{"date":"2024-03-08","current":26.210688,"twenty":25.395134,"median":30.572064,"eighty":35.667709,"marketCap":35136000000},{"date":"2024-03-15","current":30.241869,"twenty":25.409765,"median":30.44783,"eighty":35.490153,"marketCap":40504000000},{"date":"2024-03-22","current":31.217759,"twenty":25.435494,"median":30.569793,"eighty":35.18968,"marketCap":41772800000},{"date":"2024-03-28","current":26.416103,"twenty":25.461641,"median":30.551779,"eighty":34.970062,"marketCap":41528800000},{"date":"2024-04-05","current":26.713065,"twenty":25.484582,"median":30.44783,"eighty":34.88282,"marketCap":41968000000},{"date":"2024-04-12","current":27.194611,"twenty":25.506915,"median":30.285025,"eighty":34.259259,"marketCap":42748800000},{"date":"2024-04-19","current":29.268508,"twenty":25.516475,"median":30.168532,"eighty":34.060481,"marketCap":45969600000},{"date":"2024-04-26","current":29.89571,"twenty":25.531167,"median":29.89571,"eighty":33.867614,"marketCap":46896800000},{"date":"2024-05-03","current":31.286129,"twenty":25.569811,"median":29.89571,"eighty":33.72816,"marketCap":49044000000},{"date":"2024-05-10","current":35.317002,"twenty":25.600357,"median":30.150227,"eighty":34.911901,"marketCap":51288800000},{"date":"2024-05-17","current":33.551674,"twenty":25.608792,"median":30.245106,"eighty":35.034138,"marketCap":48653600000},{"date":"2024-05-24","current":33.729665,"twenty":25.66112,"median":30.409033,"eighty":35.021714,"marketCap":48800000000},{"date":"2024-05-31","current":34.458991,"twenty":25.697876,"median":30.512617,"eighty":34.936642,"marketCap":49905929000},{"date":"2024-06-07","current":35.513458,"twenty":25.700826,"median":30.572064,"eighty":35.034138,"marketCap":51369298000},{"date":"2024-06-14","current":33.485895,"twenty":25.715973,"median":30.610294,"eighty":35.023883,"marketCap":48392099000},{"date":"2024-06-21","current":32.121521,"twenty":25.745773,"median":30.694377,"eighty":34.964455,"marketCap":46323198000},{"date":"2024-06-28","current":32.099848,"twenty":25.775731,"median":30.739187,"eighty":34.884174,"marketCap":46272737000},{"date":"2024-07-05","current":29.936022,"twenty":25.803458,"median":30.671209,"eighty":34.879736,"marketCap":43144155000},{"date":"2024-07-12","current":29.087996,"twenty":25.812746,"median":30.592469,"eighty":34.858532,"marketCap":41983552000},{"date":"2024-07-19","current":27.898783,"twenty":25.84406,"median":30.569793,"eighty":34.80307,"marketCap":40267878000},{"date":"2024-07-26","current":27.412372,"twenty":25.847354,"median":30.44783,"eighty":34.722361,"marketCap":39712807000},{"date":"2024-08-02","current":26.870727,"twenty":25.853895,"median":30.347362,"eighty":34.692602,"marketCap":38905431000},{"date":"2024-08-09","current":29.53175,"twenty":25.868681,"median":30.263126,"eighty":34.580226,"marketCap":43043233000},{"date":"2024-08-16","current":27.651468,"twenty":25.880225,"median":30.20526,"eighty":34.54918,"marketCap":40318339000},{"date":"2024-08-23","current":20.295155,"twenty":25.847354,"median":30.132576,"eighty":34.503268,"marketCap":39157736000},{"date":"2024-08-30","current":21.43279,"twenty":25.766624,"median":29.936022,"eighty":34.476088,"marketCap":41630325000},{"date":"2024-09-06","current":20.565575,"twenty":25.695677,"median":29.843348,"eighty":34.445054,"marketCap":39965112000},{"date":"2024-09-13","current":18.849184,"twenty":25.540828,"median":29.786096,"eighty":34.363297,"marketCap":36533764000},{"date":"2024-09-20","current":20.082561,"twenty":25.484582,"median":29.694562,"eighty":34.259259,"marketCap":39157736000},{"date":"2024-09-27","current":24.850231,"twenty":25.394448,"median":29.657792,"eighty":34.060481,"marketCap":48745326000},{"date":"2024-10-04","current":29.382648,"twenty":25.395362,"median":29.624666,"eighty":34.023673,"marketCap":57374157000},{"date":"2024-10-10","current":27.207172,"twenty":25.409765,"median":29.557165,"eighty":33.926357,"marketCap":52782206000},{"date":"2024-10-18","current":27.08831,"twenty":25.435494,"median":29.436062,"eighty":33.784845,"marketCap":52277596000},{"date":"2024-10-25","current":27.691447,"twenty":25.469288,"median":29.344363,"eighty":33.707844,"marketCap":53438199000},{"date":"2024-11-01","current":28.012496,"twenty":25.497982,"median":29.274876,"eighty":33.690002,"marketCap":54094192000},{"date":"2024-11-08","current":29.463901,"twenty":25.512651,"median":29.272452,"eighty":33.684759,"marketCap":56465859000},{"date":"2024-11-15","current":26.265769,"twenty":25.52529,"median":29.194481,"eighty":33.660087,"marketCap":49956390000},{"date":"2024-11-22","current":26.278217,"twenty":25.56015,"median":29.088985,"eighty":33.628618,"marketCap":49956390000},{"date":"2024-11-29","current":26.561468,"twenty":25.595136,"median":29.046664,"eighty":33.578085,"marketCap":50461000000},{"date":"2024-12-06","current":27.316407,"twenty":25.595136,"median":28.89327,"eighty":33.512207,"marketCap":51772986000},{"date":"2024-12-13","current":27.527865,"twenty":25.608792,"median":28.855293,"eighty":33.470601,"marketCap":52126213000},{"date":"2024-12-20","current":27.519045,"twenty":25.66112,"median":28.7635,"eighty":33.433798,"marketCap":51823447000},{"date":"2024-12-27","current":26.95045,"twenty":25.695677,"median":28.729978,"eighty":33.410147,"marketCap":50713305000},{"date":"2025-01-03","current":25.718533,"twenty":25.700075,"median":28.694216,"eighty":33.386493,"marketCap":48442560000},{"date":"2025-01-10","current":26.596222,"twenty":25.605578,"median":28.598093,"eighty":33.385259,"marketCap":49905929000},{"date":"2025-01-17","current":28.4557,"twenty":25.610934,"median":28.581538,"eighty":33.383573,"marketCap":53438199000},{"date":"2025-01-24","current":29.058848,"twenty":25.694577,"median":28.62658,"eighty":33.365541,"marketCap":54912816000},{"date":"2025-01-28","current":30.995109,"twenty":25.696776,"median":28.668851,"eighty":33.362531,"marketCap":58878741600},{"date":"2025-02-07","current":31.279146,"twenty":25.700576,"median":28.706002,"eighty":33.347316,"marketCap":59082122400},{"date":"2025-02-14","current":32.46032,"twenty":25.708209,"median":28.7635,"eighty":33.295849,"marketCap":61166775600},{"date":"2025-02-21","current":32.605291,"twenty":25.726297,"median":28.850334,"eighty":33.213923,"marketCap":61776918000},{"date":"2025-02-28","current":33.709306,"twenty":25.745773,"median":28.875802,"eighty":33.347316,"marketCap":63658190400},{"date":"2025-03-07","current":37.167941,"twenty":25.761386,"median":29.014465,"eighty":33.385999,"marketCap":70471447200},{"date":"2025-03-14","current":37.985438,"twenty":25.781535,"median":29.070262,"eighty":33.525362,"marketCap":72047648400},{"date":"2025-03-21","current":37.329923,"twenty":25.803863,"median":29.089974,"eighty":33.667635,"marketCap":70776518400},{"date":"2025-03-28","current":31.329348,"twenty":25.820414,"median":29.153791,"eighty":33.6911,"marketCap":69149472000},{"date":"2025-04-03","current":32.960917,"twenty":25.84406,"median":29.176551,"eighty":33.68679,"marketCap":72606945600}],"updateTime":1744061575462}}}